clinical-trials.jpg

Pamrevlumab Trials

Pamrevlumab Trials

Pamrevlumab, our proprietary fully human antibody, targets connective tissue growth factor (CTGF), the central mediator of tissue remodeling and fibrosis. Pamrevlumab represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body. Pamrevlumab is in Phase 3 clinical studies for the treatment idiopathic pulmonary fibrosis, Duchenne muscular dystrophy and pancreatic cancer.

Idiopathic Pulmonary Fibrosis

ZEPHYRUS Study – FG-3019-091 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

zephyrus_II_medium.png

ZEPHYRUS II Study – FG-3019-095 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

For more information on these studies, please contact

Duchenne Muscular Dystrophy
lelantos.png

LELANTOS Study – FG-3019-093 A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

Learn more about pamrevlumab, DMD and the purpose of the LELANTOS study here, and download a printable version of this resource 

LELANTOS_two_small.jpg

LELANTOS TWO Study – FG-3019-094 A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Ambulatory Duchenne Muscular Dystrophy (DMD)

Learn more about pamrevlumab, DMD and the purpose of the LELANTOS study here, and download a printable version of this resource 

For more information on these studies, please contact

Pancreatic Cancer
lapis.png

LAPIS Study – FG-3019-087, Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination with Gemcitabine Plus Nab-paclitaxel (G/NP) as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer

For more information on the study, please contact 

PanCAN Logo Large CMYK.jpg

Precision PromiseSM Platform Study, Phase 2/3, Randomized, Open-label, A Multi-Center Trial Evaluating Multiple Regimens in Patients with Stage IV Metastatic Pancreatic Cancer

For more information on this study, please visit